The global Cancer Vaccines Market is expected to garner a market value of US$ 9 Billion in 2023 and is expected to accumulate a market value of US$ 24.22 Billion by registering a CAGR of 12% in the forecast period 2023 to 2033. The market for Cancer Vaccines registered a CAGR of 9% in the historical period 2018 to 2022.
The Cancer Vaccines market is a segment of the healthcare industry that deals with the effective management of the condition. The Cancer Vaccines market offers a range of vaccines that uses the body's own immune system to recognize and attack cancer cells. There are two main types of cancer vaccines: preventive vaccines and therapeutic vaccines. Preventive vaccines are designed to prevent certain types of cancer, such as the HPV vaccine that helps prevent cervical cancer. Therapeutic vaccines, on the other hand, are designed to treat cancer by stimulating the immune system to recognize and attack cancer cells.
Report Attribute | Details |
---|---|
Expected Market Value (2023) | US$ 9 Billion |
Anticipated Forecast Value (2033) | US$ 24.22 Billion |
Projected Growth Rate (2023 to 2033) | 12% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider, Future Market Insights- the market for Cancer Vaccines reflected a value of 9% during the historical period, 2018 to 2022. During this period, the demand for treatment for Cancer increased, driven by factors such as increasing incidence of cancer, growing awareness about cancer prevention and treatment, and technological advancements in vaccine development.
Looking ahead to the period from 2023 to 2033, the cancer vaccines market is expected to continue growing, although at a slightly slower pace than in the previous period. Cancer is expected to remain a major health concern globally, which will drive demand for cancer vaccines. In recent years, several new cancer vaccine options have emerged for Cancer, pushing the market for Cancer Vaccines is expected to register a CAGR of 12% in the forecast period 2023 to 2033.
Growing advancements in diagnostic and treatment options to push the market growth
The Cancer Vaccines Market is expected to experience significant growth in the coming years, driven by several factors. According to the World Health Organization (WHO), cancer is the second leading cause of death worldwide, responsible for an estimated 9.6 million deaths in 2018. The most common types of cancer worldwide include lung, breast, colorectal, prostate, stomach, and liver cancer.
The increasing prevalence of cancer has led to the development of new technologies such as gene editing and personalized medicine is enabling the development of more effective cancer vaccines. The prevalence of cancer varies by region and demographic group. Low- and middle-income countries are disproportionately affected by cancer, with over 60% of new cancer cases and 70% of cancer deaths occurring in these countries. This is due to a combination of factors including lack of access to prevention and early detection services, limited resources for cancer vaccine, and higher rates of risk factors such as tobacco use and infectious diseases.
Cancer is a major public health concern globally, with millions of new cases diagnosed each year. Overall, the prevalence of cancer is expected to continue to increase globally, with an estimated 29.5 million new cancer cases and 16.5 million cancer deaths expected by 2040, according to the International Agency for Research on Cancer (IARC). The combination of these factors is expected to drive significant growth in the Cancer vaccines market in the coming years.
Expensive Cost of Treatment to restrict Market Growth
Cancer is a complex disease, and its nature differs from person to person. As a result, developing a vaccine that can effectively treat all forms of cancer is a major challenge. The current cancer vaccines on the market have limited success rates, and there is a need to develop more effective vaccines to meet the growing demand for cancer treatment.
Many people are not aware of the benefits of cancer vaccines, and this can limit their adoption and use. Furthermore, regulatory challenges can limit the development and approval of new vaccines for Cancer, which can slow down progress in the field. Some people may be resistant to vaccines, and this can limit the effectiveness of cancer vaccines.
Increasing Advancements in the Diagnostic Techniques Shaping Landscape for Cancer Vaccines in South & East Asia
The Cancer Vaccines Market in the South and East Asia region is growing, driven by several factors such as increasing cancer incidence, growing awareness about cancer prevention, and the rising demand for personalized medicine are driving the growth of the cancer vaccine market in the region. Additionally, the increasing adoption of advanced technologies such as Next-generation sequencing (NGS) data analysis and bioinformatics in cancer research is expected to further fuel market growth.
In South and East Asia, the Cancer Vaccines Market is expected to witness significant growth in the coming years, driven by factors such as increasing cancer incidence, growing demand for innovative treatment options, and rising investments in cancer research and development.
In addition, there is a growing awareness about the disease in the region, which is leading to more frequent diagnoses and better access to vaccines. Governments and healthcare organizations are also taking steps to improve the diagnosis and treatment of Cancer, which is helping to drive growth in the market.
Increasing Focus on Technological advancements Shaping Landscape for Cancer Vaccines in North America
North America is anticipated to acquire a market share of about 40% in the forecast period. As awareness about cancer vaccines increases among the general population, more people are opting for these vaccines as a preventive measure against cancer. North America has some of the world's leading research institutions, which are dedicated to developing new and effective cancer vaccines. This has led to the development of several innovative cancer vaccines in recent years.
Additionally, The regulatory environment for cancer vaccines in North America is favorable, with regulatory agencies such as the FDA in the USA providing fast-track approval for promising cancer vaccines. Healthcare expenditure in the region is increasing, which has led to increased investment in cancer treatment and prevention, including cancer vaccines.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Recombinant cancer vaccines segment to hold a significant share and push market growth
Currently, the recombinant cancer vaccines segment is expected to account for a significant share of the market. Recombinant cancer vaccines are developed using genetic engineering technology, which enables the production of specific proteins that can stimulate the immune system to attack cancer cells. This technology has shown promising results in clinical trials and has been approved for use in the treatment of certain types of cancer, such as prostate cancer and melanoma.
Therapeutic cancer vaccines to take the lead and drive market growth
Currently, the therapeutic cancer vaccines segment is expected to account for a significant share of the market. Therapeutic cancer vaccines are designed to stimulate the immune system to attack existing cancer cells in patients who have already been diagnosed with cancer. These vaccines are being developed for a variety of cancer types and have shown promising results in clinical trials.
Key players in the market include companies such as Advaxis Inc., Amgen Inc., Dynavax Technologies Corporation, Generex Biotechnology Corporation, GlaxoSmithKline plc, Immunocellular Therapeutics, Ltd, Merck & Co., Inc., Vaccinogen, Inc., F Hoffmann-La Roche AG, and OSE Immunotherapeutics, along with healthcare providers and technology companies among other global players.
The firm developed one of the most widely-distributed Covid-19 vaccines in collaboration with USA pharmaceutical firm Pfizer. The collaboration will cover various cancer types and infectious diseases affecting collectively hundreds of millions of people worldwide.
Report Attribute | Details |
---|---|
Market Value in 2023 | US$ 9 Billion |
Market Value in 2033 | US$ 24.22 Billion |
Growth Rate | CAGR of 12% from 2023 to 2033 |
Base Year for Estimation | 2022 |
Historical Data | 2018 to 2022 |
Forecast Period | 2023 to 2033 |
Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
Segments Covered |
|
Regions Covered |
|
Key Countries Profiled |
|
Key Companies Profiled | Advaxis Inc., Amgen Inc., Dynavax Technologies Corporation, Generex Biotechnology Corporation, GlaxoSmithKline plc, Immunocellular Therapeutics, Ltd, Merck & Co., Inc., Vaccinogen, Inc., F Hoffmann-La Roche AG, and OSE Immunotherapeutics |
Customization | Available Upon Request |
From 2018 to 2022, the Cancer Vaccines Market grew at a CAGR of 9%.
The global Cancer Vaccines Market is expected to grow with a 12% CAGR during 2023 to 2033.
As of 2033, the Cancer Vaccines Market is expected to reach US$ 24.22 Billion
According to the FMI analysis, the recombinant cancer vaccines segment accounts for the largest market share.
North America is expected to possess 40% market share for the Cancer Vaccines Market.
The Asia Pacific market is projected to increase significantly throughout the forecast period, with a share of 20% during the forecast period.
The market is expected to record a 12% CAGR throughout 2033.
Innovations in diagnostics and treatment options are likely to grow the market.
Recombinant cancer vaccines to dominate the market.
North America to acquire a 40% share during the forecast period.
The market is expected to accumulate a value of US$ 24.22 billion by 2033.
1. Executive Summary | Cancer Vaccines Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Technology 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Technology, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Technology, 2023 to 2033 5.3.1. Recombinant Cancer Vaccines 5.3.2. Whole-cell Cancer Vaccines 5.3.3. Viral Vector & DNA Cancer Vaccines 5.3.4. Antigen/Adjuvant Cancer Vaccines 5.4. Y-o-Y Growth Trend Analysis By Technology, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Technology, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Method 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Treatment Method, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Method, 2023 to 2033 6.3.1. Preventive Vaccine 6.3.2. Therapeutic Vaccine 6.4. Y-o-Y Growth Trend Analysis By Treatment Method, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Treatment Method, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Application, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2023 to 2033 7.3.1. Prostate Cancer 7.3.2. Cervical Cancer 7.3.3. Other Applications 7.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. South Asia 8.3.5. East Asia 8.3.6. Oceania 8.3.7. MEA 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Technology 9.2.3. By Treatment Method 9.2.4. By Application 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Technology 9.3.3. By Treatment Method 9.3.4. By Application 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Technology 10.2.3. By Treatment Method 10.2.4. By Application 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Technology 10.3.3. By Treatment Method 10.3.4. By Application 10.4. Key Takeaways 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. United kingdom 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Technology 11.2.3. By Treatment Method 11.2.4. By Application 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Technology 11.3.3. By Treatment Method 11.3.4. By Application 11.4. Key Takeaways 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Malaysia 12.2.1.3. Singapore 12.2.1.4. Thailand 12.2.1.5. Rest of South Asia 12.2.2. By Technology 12.2.3. By Treatment Method 12.2.4. By Application 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Technology 12.3.3. By Treatment Method 12.3.4. By Application 12.4. Key Takeaways 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Technology 13.2.3. By Treatment Method 13.2.4. By Application 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Technology 13.3.3. By Treatment Method 13.3.4. By Application 13.4. Key Takeaways 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. Australia 14.2.1.2. New Zealand 14.2.2. By Technology 14.2.3. By Treatment Method 14.2.4. By Application 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Technology 14.3.3. By Treatment Method 14.3.4. By Application 14.4. Key Takeaways 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Technology 15.2.3. By Treatment Method 15.2.4. By Application 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Technology 15.3.3. By Treatment Method 15.3.4. By Application 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Technology 16.1.2.2. By Treatment Method 16.1.2.3. By Application 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Technology 16.2.2.2. By Treatment Method 16.2.2.3. By Application 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Technology 16.3.2.2. By Treatment Method 16.3.2.3. By Application 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Technology 16.4.2.2. By Treatment Method 16.4.2.3. By Application 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Technology 16.5.2.2. By Treatment Method 16.5.2.3. By Application 16.6. United kingdom 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Technology 16.6.2.2. By Treatment Method 16.6.2.3. By Application 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Technology 16.7.2.2. By Treatment Method 16.7.2.3. By Application 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Technology 16.8.2.2. By Treatment Method 16.8.2.3. By Application 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Technology 16.9.2.2. By Treatment Method 16.9.2.3. By Application 16.10. India 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Technology 16.10.2.2. By Treatment Method 16.10.2.3. By Application 16.11. Malaysia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Technology 16.11.2.2. By Treatment Method 16.11.2.3. By Application 16.12. Singapore 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Technology 16.12.2.2. By Treatment Method 16.12.2.3. By Application 16.13. Thailand 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Technology 16.13.2.2. By Treatment Method 16.13.2.3. By Application 16.14. China 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Technology 16.14.2.2. By Treatment Method 16.14.2.3. By Application 16.15. Japan 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Technology 16.15.2.2. By Treatment Method 16.15.2.3. By Application 16.16. South Korea 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Technology 16.16.2.2. By Treatment Method 16.16.2.3. By Application 16.17. Australia 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Technology 16.17.2.2. By Treatment Method 16.17.2.3. By Application 16.18. New Zealand 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Technology 16.18.2.2. By Treatment Method 16.18.2.3. By Application 16.19. GCC Countries 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Technology 16.19.2.2. By Treatment Method 16.19.2.3. By Application 16.20. South Africa 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Technology 16.20.2.2. By Treatment Method 16.20.2.3. By Application 16.21. Israel 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Technology 16.21.2.2. By Treatment Method 16.21.2.3. By Application 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Technology 17.3.3. By Treatment Method 17.3.4. By Application 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Advaxis Inc. 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Amgen Inc. 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Dynavax Technologies Corporation 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Generex Biotechnology Corporation 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. GlaxoSmithKline plc 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Immunocellular Therapeutics, Ltd 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Merck & Co., Inc. 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Vaccinogen, Inc. 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. F Hoffmann-La Roche AG 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. OSE Immunotherapeutics 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports